{"classes":[{"categories":[{"measurements":[{"comment":"Median, lower and upper limit of CI was not estimable because the curve's upper CI bound had not crossed 50% survival threshold.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of CI was not estimable because the curve's upper bound CI had not crossed 50% survival threshold.","groupId":"OG001","lowerLimit":"4.9","upperLimit":"NA","value":"8.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"Time to pain progression was defined as the time duration (in months) between the date of randomization and the date of first documented pain progression. Pain progression, in participants with no pain or stable pain at Baseline was defined as increase of \\>=30% from baseline in the BPI-SF pain intensity score observed at 2 consecutive evaluations \\>=3 weeks apart without decrease in analgesic usage score or increase in analgesic usage score (calculated from analgesic use data, with non-narcotic medications assigned value of 1 point and narcotic medications assigned 4 points) \\>=30%. The BPI-SF is a self-administered questionnaire developed to assess the severity of pain on a 0-10 categorical scale where 0=no pain, 10=pain as bad as you can imagine. Higher scores indicated worst outcomes. Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Cabazitaxel 25 mg/m\\^2 IV infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic G-CSF as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).","id":"OG000","title":"Cabazitaxel"},{"description":"Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).","id":"OG001","title":"Abiraterone Acetate or Enzalutamide"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on subset of ITT population (any participant who had been allocated to a randomized treatment, analyzed according to group allocated) with baseline assessment and at least one post-baseline assessment before any further anti-cancer therapy for BPI-SF pain intensity score.","reportingStatus":"POSTED","timeFrame":"Baseline until pain progression or data cut-off whichever comes first (maximum duration: up to 141 weeks)","title":"Time to Pain Progression","type":"SECONDARY","unitOfMeasure":"months"}